

# Maria Rosaria Raspollini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/780252/publications.pdf>

Version: 2024-02-01

83  
papers

2,060  
citations

304602

22  
h-index

243529

44  
g-index

85  
all docs

85  
docs citations

85  
times ranked

2575  
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of COVID-19 in prostate tissue inflammation: first pathological evidence. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 370-372.	2.0	4
2	Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 727.	1.1	3
3	An introduction to the <scp>WHO</scp> 5th edition 2022 classification of testicular tumours. <i>Histopathology</i> , 2022, 81, 459-466.	1.6	32
4	Potential utility of a 4-marker immunohistochemistry panel to predict response to cisplatin-based neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: a single-center preliminary experience. <i>Minerva Urology and Nephrology</i> , 2021, 73, 424-427.	1.3	4
5	Preimplantation Factor immunohistochemical expression correlates with prostate cancer aggressiveness. <i>International Journal of Biological Markers</i> , 2020, 35, 82-90.	0.7	2
6	TFE3 Gene Rearrangement in Perivascular Epithelioid Cell Neoplasm (PEComa) of the Genitourinary Tract. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e692-e697.	0.9	12
7	Acute kidney injury promotes development of papillary renal cell adenoma and carcinoma from renal progenitor cells. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	46
8	Clinicopathologic analysis of upper urinary tract carcinoma with variant histology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 111-120.	1.4	24
9	pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 3-16.	1.4	8
10	Staging and Reporting of Renal Cell Carcinomas. , 2020, , 423-436.		0
11	Urothelial Carcinoma, Nested Type. <i>Encyclopedia of Pathology</i> , 2020, , 1-3.	0.0	0
12	Urothelial Carcinoma, Plasmacytoid Type. <i>Encyclopedia of Pathology</i> , 2020, , 486-489.	0.0	0
13	Urothelial Carcinoma, Clear Cell (Glycogen-Rich) Type. <i>Encyclopedia of Pathology</i> , 2020, , 1-3.	0.0	0
14	Urothelial Carcinoma, Lipid-Rich Type. <i>Encyclopedia of Pathology</i> , 2020, , 475-477.	0.0	0
15	Cystitis, Granulomatous Type. <i>Encyclopedia of Pathology</i> , 2020, , 56-57.	0.0	0
16	Urothelial Carcinoma, Nested Type. <i>Encyclopedia of Pathology</i> , 2020, , 484-486.	0.0	0
17	Urothelial Carcinoma, Giant Cell Type. <i>Encyclopedia of Pathology</i> , 2020, , 468-469.	0.0	0
18	Urothelial Carcinoma, Clear Cell (Glycogen-Rich) Type. <i>Encyclopedia of Pathology</i> , 2020, , 466-467.	0.0	0

#	ARTICLE	IF	CITATIONS
19	Cancer-associated fibroblasts promote prostate cancer malignancy via metabolic rewiring and mitochondrial transfer. <i>Oncogene</i> , 2019, 38, 5339-5355.	2.6	163
20	â™,â™€ Clear Cell Tumors of the Kidney and the Gynecologic Tract. , 2019, , 173-188.		0
21	â™,â™€ Transitional Cell Tumors of the Bladder. , 2019, , 254-273.		0
22	â™,â™€ Pathology of the Female and Male Urethra. , 2019, , 285-303.		0
23	Variants and new entities of bladder cancer. <i>Histopathology</i> , 2019, 74, 77-96.	1.6	120
24	Urothelial Carcinoma: Lipid-Rich Type. <i>Encyclopedia of Pathology</i> , 2019, , 1-2.	0.0	0
25	Urothelial Carcinoma, Giant Cell Type. <i>Encyclopedia of Pathology</i> , 2019, , 1-2.	0.0	0
26	Cystitis, Granulomatous Type. <i>Encyclopedia of Pathology</i> , 2019, , 1-3.	0.0	0
27	Urothelial Carcinoma, Plasmacytoid Type. <i>Encyclopedia of Pathology</i> , 2019, , 1-4.	0.0	0
28	Intratumoural heterogeneity may hinder precision medicine strategies in patients with clear cell renal cell carcinoma. <i>Journal of Clinical Pathology</i> , 2018, 71, 467-471.	1.0	6
29	The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. <i>Radiotherapy and Oncology</i> , 2018, 127, 404-416.	0.3	241
30	The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 641-655.	1.2	336
31	Tumorâ€™ parenchyma interface and long-term oncologic outcomes after robotic tumor enucleation for sporadic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 527.e1-527.e11.	0.8	35
32	The central role of the pathologist in the management of patients with cervical cancer: ESGO/ESTRO/ESP guidelines. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 45-54.	1.4	5
33	The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 919-936.	1.4	127
34	Unusual asymptomatic presentation of bladder cancer metastatic to the penis. <i>Pathology Research and Practice</i> , 2017, 213, 717-720.	1.0	6
35	Lymphoepithelioma-like carcinoma of the upper urinary tract. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 703-709.	1.4	22
36	Spectrum of genetic mutations in de novo PUNLMP of the urinary bladder. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 761-767.	1.4	29

#	ARTICLE	IF	CITATIONS
37	A contemporary series of renal masses with emphasis on recently recognized entities and tumors of low malignant potential: A report based on 624 consecutive tumors from a single tertiary center. <i>Pathology Research and Practice</i> , 2017, 213, 804-808.	1.0	10
38	Iatrogenic changes in the urinary tract. <i>Histopathology</i> , 2017, 70, 10-25.	1.6	25
39	Variants of Bladder Cancer: The Pathologist's Point of View. <i>European Urology Supplements</i> , 2017, 16, 210-222.	0.1	16
40	Concomitant bladder cancer and prostate cancer: challenges and controversies. <i>Nature Reviews Urology</i> , 2017, 14, 620-629.	1.9	17
41	Conservative Approach for a Solitary Fibrous Tumor of the Kidney. <i>Urologia</i> , 2016, 83, 221-223.	0.3	0
42	Genetic mutations in accordance with a low malignant potential tumour are not demonstrated in clear cell papillary renal cell carcinoma. <i>Journal of Clinical Pathology</i> , 2016, 69, 547-550.	1.0	12
43	Synchronous clear cell renal cell carcinoma and multilocular cystic renal cell neoplasia of low malignant potential: A clinico-pathologic and molecular study. <i>Pathology Research and Practice</i> , 2016, 212, 471-474.	1.0	2
44	T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-II $\beta$ , survivin, and E-cadherin. <i>Human Pathology</i> , 2016, 57, 78-84.	1.1	24
45	Conservative Treatment of Serous Borderline Paratesticular Tumor in a Pediatric Patient. <i>Urology</i> , 2016, 89, 123-125.	0.5	6
46	Unlike in clear cell renal cell carcinoma, KRAS is not mutated in multilocular cystic clear cell renal cell neoplasm of low potential. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 467, 687-693.	1.4	13
47	Robot-Assisted Laparoscopic Vesiculectomy for Large Seminal Vesicle Cystadenoma: A Case Report and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e369-e373.	0.9	14
48	Histopathological Validation of the Surface-Intermediate-Base Margin Score for Standardized Reporting of Resection Technique during Nephron Sparing Surgery. <i>Journal of Urology</i> , 2015, 194, 916-922.	0.2	25
49	The R.E.N.A.L. Nephrometric Nomogram Cannot Accurately Predict Malignancy or Aggressiveness of Small Renal Masses Amenable to Partial Nephrectomy. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 366-372.	0.9	21
50	Pathological characteristics and prognostic effect of peritumoral capsule penetration in renal cell carcinoma after tumor enucleation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 50.e15-50.e22.	0.8	41
51	A Proposed Score for Assessing Progression in pT1 High-grade Urothelial Carcinoma of the Bladder. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2013, 21, 218-227.	0.6	9
52	Necrotizing Palisading Granuloma of the Bladder in an Otherwise Healthy Young Man. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 679-680.	1.2	3
53	Polypoid Intestinal Metaplasia of the External Urethral Meatus. <i>International Journal of Surgical Pathology</i> , 2012, 20, 640-642.	0.4	2
54	The Challenging Diagnosis of the Rhabdoid Carcinoma of the Pelvis. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2012, 20, 177-183.	0.6	4

#	ARTICLE	IF	CITATIONS
55	Plasmacytoid urothelial carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis of a case series. <i>Human Pathology</i> , 2011, 42, 1149-1158.	1.1	65
56	Blue nevus of the prostate: incidental finding in radical prostatectomy specimen with a pre-operative echographic image of peripheral hypoechogenic nodule. <i>Archivio Italiano Di Urologia Andrologia</i> , 2011, 83, 210-2.	0.4	2
57	Primitive Testicular Leiomyosarcoma. <i>Pathology and Oncology Research</i> , 2010, 16, 177-179.	0.9	4
58	Problems Arising in the Diagnosis of Primary Ovarian Transitional Cell Carcinoma After the Occurrence of a Transitional Cell Carcinoma of the Bladder. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2009, 17, 178-183.	0.6	1
59	Langerhans cells in lichen sclerosus of the vulva and lichen sclerosus evolving in vulvar squamous cell carcinoma. <i>Histology and Histopathology</i> , 2009, 24, 331-6.	0.5	2
60	Cytokeratin (AE1/AE3) in addition to Î±-methylacyl coenzyme A racemase (P504S), 34-beta-E12, and p63 stains in evaluation of surgical specimens after hormonal therapy for prostatic adenocarcinoma. <i>Human Pathology</i> , 2008, 39, 304-305.	1.1	0
61	In situ adenocarcinoma and squamous carcinoma of uterine cervix. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2007, 134, 249-253.	0.5	2
62	The role of angiogenesis and COX-2 expression in the evolution of vulvar lichen sclerosus to squamous cell carcinoma of the vulva. <i>Gynecologic Oncology</i> , 2007, 106, 567-571.	0.6	18
63	CA-125 level preoperative assessment in early and advanced ovarian carcinoma. <i>Gynecologic Oncology</i> , 2007, 107, 356-357.	0.6	1
64	A comparative analysis of lichen sclerosus of the vulva and lichen sclerosus that evolves to vulvar squamous cell carcinoma. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 197, 592.e1-592.e5.	0.7	26
65	Cyclooxygenase-2: A novel target in human solid tumors. <i>Current Oncology Reports</i> , 2007, 9, 96-101.	1.8	4
66	Characterization of tumor specimens for a targeted therapy in metastatic renal cell carcinoma patients. <i>Current Oncology Reports</i> , 2007, 9, 331-331.	1.8	0
67	HER-2/neu and bcl-2 in Ovarian Carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2006, 14, 181-186.	0.6	16
68	COX-2 and preoperative CA-125 level are strongly correlated with survival and clinical responsiveness to chemotherapy in ovarian cancer. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2006, 85, 493-498.	1.3	13
69	Cyclooxygenase-2, angiogenesis, tumor cell proliferation, P-glycoprotein in advanced ovarian serous carcinoma. <i>American Journal of Obstetrics and Gynecology</i> , 2006, 194, 1203.	0.7	1
70	p16(INK4a) expression in urinary bladder carcinoma. <i>Archivio Italiano Di Urologia Andrologia</i> , 2006, 78, 97-100.	0.4	8
71	Immunohistochemistry in the Differential Diagnosis Between Primary and Secondary Intestinal Adenocarcinoma of the Urinary Bladder. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2005, 13, 358-362.	0.6	39
72	HER-2/neu oncogene in uterine carcinosarcoma on tamoxifen therapy. <i>Pathology Research and Practice</i> , 2005, 201, 141-144.	1.0	6

#	ARTICLE	IF	CITATIONS
73	COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?. <i>Gynecologic Oncology</i> , 2005, 96, 159-167.	0.6	58
74	Vulvar basal cell carcinoma: retrospective study and review of literature. <i>Gynecologic Oncology</i> , 2005, 97, 192-194.	0.6	97
75	Correlation of Epidermal Growth Factor Receptor Expression with Tumor Microdensity Vessels and with Vascular Endothelial Growth Factor Expression in Ovarian Carcinoma. <i>International Journal of Surgical Pathology</i> , 2005, 13, 135-142.	0.4	47
76	Difference in expression of matrix metalloproteinase-2 and matrix metalloproteinase-9 in patients with persistent ovarian cysts. <i>Fertility and Sterility</i> , 2005, 84, 1049-1052.	0.5	5
77	Differential Diagnosis between Uterine Carcinosarcoma versus Carcinoma with Sarcomatous Metaplasia: An Immunohistochemical and Ultrastructural Case Study. <i>Ultrastructural Pathology</i> , 2005, 29, 149-155.	0.4	3
78	Pathologic Quiz Case: A 53-Year-Old Woman With Bilateral Ovarian Tumors. <i>Archives of Pathology and Laboratory Medicine</i> , 2005, 129, e103-e104.	1.2	1
79	c-Kit Expression in Patients with Uterine Leiomyosarcomas. <i>Clinical Cancer Research</i> , 2004, 10, 3500-3503.	3.2	51
80	Utility of CDX-2 in Distinguishing Between Primary and Secondary (Intestinal) Mucinous Ovarian Carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2004, 12, 127-131.	0.6	43
81	COX-2 status in relation to tumor microvessel density and VEGF expression: analysis in ovarian carcinoma patients with low versus high survival rates. <i>Oncology Reports</i> , 2004, 11, 309-13.	1.2	22
82	Multilocular cystic nephroma in adults. <i>Archivio Italiano Di Urologia Andrologia</i> , 2004, 76, 40-1.	0.4	0
83	Primary Cervical Adenocarcinoma With Intestinal Differentiation and Colonic Carcinoma Metastatic to Cervix: An Investigation Using Cdx-2 and a Limited Immunohistochemical Panel. <i>Archives of Pathology and Laboratory Medicine</i> , 2003, 127, 1586-1590.	1.2	47